In an investor relations interview, ASKA Pharmaceutical Holdings Co.,Ltd. stated that it aims to become a specialty pharmaceutical company centered on hormone preparations, particularly in internal medicine, obstetrics and gynecology, and urology, and outlined plans to strengthen its overseas expansion and drug discovery investment to support long-term growth.
Based on an investor relations interview conducted on 28 January 2025, this column outlines ASKA Pharmaceutical Holdings Co.,Ltd.'s strategy of developing its business around hormone technologies. Tracing the company's history from its founding, the interview confirms its commitment to pursuing a focused strategy in the fields of internal medicine, obstetrics and gynecology, and urology.
The current business comprises 3 main pillars: prescription pharmaceuticals, animal health and diagnostics. Its high domestic market share, particularly for thyroid hormone preparations, was highlighted as a key strength.
Its growth strategy includes efforts to develop ion channel drugs and promote overseas expansion, including the acquisition of shares in Ha Tay Pharmaceutical Joint Stock Company in Vietnam and plans to make it a consolidated subsidiary.
The company also plans to expand its diagnostics business and enter the B2C market by developing veterinary pharmaceuticals for the pet market and promoting new testing methods using hair and nails.